Monday, January 16, 2017

Trading Covered Calls: Alcobra Ltd. (NASDAQ:ADHD) : A Clever Covered Call Implementation - CML News


Trading Covered Calls: Alcobra Ltd. (NASDAQ:ADHD) : A Clever Covered Call Implementation
CML News
As we look at Alcobra Ltd. we note that a covered call is one of the most common implementations of an option strategy, but the analysis completed when employing the covered call often times lacks the necessary rigor especially surrounding earnings.

and more »

The Alcobra Ltd. (ADHD) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - DailyQuint


The Alcobra Ltd. (ADHD) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
DailyQuint
Alcobra Ltd. (NASDAQ:ADHD) announced its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.02. The firm earned $7.90 million during the quarter, ...

Improved Academic Performance and Medication Rebound in ... - EconoTimes


Improved Academic Performance and Medication Rebound in ...
EconoTimes
BALTIMORE, Jan. 10, 2017 -- Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according ...

and more »

The Pros and Cons of Consuming Coffee for People With ADHD - Latinos Health


Latinos Health

The Pros and Cons of Consuming Coffee for People With ADHD
Latinos Health
With the rise of today's worldwide coffee culture, there's an interesting study results that coincides with coffee, especially for people with Attention Deficit Hyperactive Disorder, or ADHD for short. The study suggests that the right amount of daily ...

Improved Academic Performance and Medication Rebound in ... - EconoTimes


Improved Academic Performance and Medication Rebound in ...
EconoTimes
BALTIMORE, Jan. 10, 2017 -- Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according ...

and more »

Dasotraline meets endpoint in adults with binge eating disorder but not ADHD - The Pharma Letter (registration)


Pharmaceutical Business Review

Dasotraline meets endpoint in adults with binge eating disorder but not ADHD
The Pharma Letter (registration)
A Phase II/III study (SEP360-221), the first of two planned pivotal studies, evaluating the novel drug candidate dasotraline in adults aged 18 to 55 years with moderate to severe binge eating disorder (BED) met the primary efficacy endpoint as well as ...
Sunovion's dasotraline improves ADHD symptoms in children in phase 2/3 studyPharmaceutical Business Review

all 2 news articles »

Dasotraline effective for binge-eating disorder, not ADHD in adults - Healio


Dasotraline effective for binge-eating disorder, not ADHD in adults
Healio
Sunovion Pharmaceuticals recently announced dasotraline, a dopamine and norepinephrine reuptake inhibitor, met its primary efficacy endpoint for moderate-to-severe binge-eating disorder in adults, but did not meet its primary endpoint for ADHD in adults.